Tetraneuron is a drug discovery company, focused on the development of a disruptive gene therapy for Alzheimer’s Disease (AD) and an Early Biomarker for this neurodegenerative condition.
Looking for a particular TETRANEURON employee's phone or email?
The TETRANEURON annual revenue was $3 million in 2026.
Angel Lucio is the CEO of TETRANEURON.
9 people are employed at TETRANEURON.
The NAICS codes for TETRANEURON are [54, 541].
The SIC codes for TETRANEURON are [87, 873].